Record mula sa primary source

MateryalPartnership / kasunduan sa lisensya

UCB partners with Cradle on AI-driven antibody engineering platform

Pumasok si UCB sa isang madiskarteng pakikipagtulungan sa Cradle upang isama ang end-to-end AI protein design platform nito sa mga napiling antibody discovery projects mula sa hit generation hanggang sa lead optimization at preclinical readiness. Ito ay nagpapalawak sa digital antibody engineering program ng UCB upang mapabilis ang pagtukoy at pag-optimize ng mga kandidato para sa malalang sakit sa immune at CNS.

Mahahalagang fact

Na-file
Nob 4, 2026, 06:00 AM
Kaganapan
Partnership / kasunduan sa lisensya
Direksyon
Neutral
Kumpiyansa
May source

Sipi mula sa source

UCB advances its digital antibody engineering program with new Cradle collaboration UCB advances its digital antibody engineering program with new Cradle collaboration News provided by Cradle; UCB Nov 04, 2026, 01:00 ET Share this article Share this article Collaboration adds Cradle's end-to-end platform to UCB's computational capabilities, supporting faster discovery of complex therapies for severe diseases BRUSSELS and AMSTERDAM , Nov. 4, 2026 /PRNewswire/ -- UCB, a global biopharmaceutical company, and Cradle, which builds a leading AI-driven protein design and engineering platform, today announced a strategic collaboration. The collaboration is the latest step in UCB's expanding digital antibody discovery and engineering program, which draws on the company's own successful antib

Press release ng kumpanya

UCB partners with Cradle on AI-driven antibody engineering platform | SimianX AI